Aubagio

Aubagio. It is an oral medication used in the treatment of relapsing-remitting multiple sclerosis, a form of the autoimmune disease that affects the central nervous system. Developed by the French pharmaceutical company Sanofi, it functions as a disease-modifying therapy designed to reduce the frequency of clinical relapses and delay the accumulation of physical disability. Its approval and use are governed by regulatory bodies such as the Food and Drug Administration in the United States and the European Medicines Agency.

Medical uses

Aubagio is indicated for the management of adult patients with relapsing-remitting multiple sclerosis. Clinical trials, including the pivotal TEMSO study, demonstrated its efficacy in significantly reducing annualized relapse rates and slowing the progression of disability as measured by the Expanded Disability Status Scale. It is not typically recommended for use in progressive forms of multiple sclerosis such as primary progressive multiple sclerosis. Treatment decisions often involve neurologists assessing patient history, magnetic resonance imaging activity, and tolerability of other agents like interferon beta-1a or glatiramer acetate.

Adverse effects

Common adverse reactions associated with Aubagio include alopecia, diarrhea, nausea, and elevated levels of alanine transaminase, necessitating regular liver function test monitoring. More serious risks involve potential hepatotoxicity and teratogenicity, which requires strict pregnancy prevention programs as mandated by the FDA's Risk Evaluation and Mitigation Strategy. Other significant concerns are peripheral neuropathy and a reversible decrease in white blood cell counts. Patients are often screened for latent tuberculosis infection prior to initiation due to immunosuppressive effects.

Pharmacology

Aubagio's active metabolite, teriflunomide, acts as a selective inhibitor of the mitochondrial enzyme dihydroorotate dehydrogenase, a key protein in the de novo pyrimidine synthesis pathway. This inhibition leads to a cytostatic effect on rapidly dividing lymphocytes, particularly T cells and B cells, which are implicated in the inflammatory processes of multiple sclerosis. The drug exhibits high plasma protein binding and has a prolonged elimination half-life, which can be accelerated using administration of cholestyramine or activated charcoal if rapid elimination is required.

History

The development of Aubagio originated from research into leflunomide, an older disease-modifying antirheumatic drug used for rheumatoid arthritis. Scientists at Sanofi identified its active metabolite, teriflunomide, as a candidate for neuroimmunology applications. Following extensive clinical development through the TERACLES program, it received its first global approval from the FDA in September 2012. Subsequent endorsements came from the European Commission and other agencies like Health Canada and the Therapeutic Goods Administration.

Society and culture

Aubagio has been a subject of discussion within organizations like the National Multiple Sclerosis Society regarding treatment accessibility and cost. It has been featured in medical guidelines from the American Academy of Neurology. The drug's teratogenic profile has influenced prescribing practices and patient counseling, paralleling discussions around other therapies like thalidomide. Its market introduction added to the competitive landscape dominated by entities such as Biogen and Novartis, influencing formularies of major insurers and programs like the National Health Service.